Alpine Investors Closes $3.4 Billion Single-Asset Continuation Transaction to Support Continued Growth of Apex Service Partners
25.10.2023 15:30:00 EEST | Business Wire | Press release
Alpine Investors (“Alpine”), a Certified B Corp people-driven private equity firm committed to building enduring software and services companies, today announced the completion of a $3.4 billion single-asset secondary market transaction to continue its partnership with Apex Service Partners (“Apex”), an HVAC, plumbing and electrical services leader and a portfolio company of Alpine Investors VII and VII-A (“Fund VII”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231025759806/en/
Founded in 2019 and headquartered in Tampa, Florida, Apex is a residential HVAC, plumbing and electrical services platform that partners with leading providers across the country. With over 8,000 employees nationwide, Apex focuses on empowering its people to build a strong network of industry leaders who can share resources, best practices and expertise in order to deliver unparalleled service to customers.
The transaction is solely dedicated to the further expansion of Apex and underscores Alpine's commitment to facilitating the next stage of growth for the services platform, as well as Alpine’s dedication to offering liquidity to its limited partners. The announcement follows the recent close of Alpine’s latest fund, Alpine Investors IX (“Fund IX”), which reached the fund’s hard cap of $4.5 billion of LP commitments. Fund IX invested $450 million in Apex alongside the continuation fund.
"Apex has a unique model that is built on combining leading brands with exceptional people,” said Graham Weaver, Founder and CEO of Alpine Investors. “The result is that Apex creates outstanding experiences for its customers and continues to experience explosive growth. We believe the extraordinary people at Apex have only begun to scratch the surface of the market opportunity ahead of them. We are excited to continue supporting their growth and to have given our investors the opportunity to participate in this collaborative secondary process.”
Commitments for Apex include contributions from Blackstone Strategic Partners, HarbourVest Partners, Lexington Partners, and Pantheon, as well as commitments from Alpine’s Fund IX. Limited partners of Fund VII were able to receive liquidity for their 2019 investments or roll a portion of their investments into the continuation fund and remain stakeholders. In line with Alpine’s investor-friendly process, limited partners were also given opportunities to combine their liquidity and rollover options to varying degrees based on their preferences.
“In just four years, Apex Service Partners has built a leading national business by serving as a force multiplier for the incredible employees and leading local brands within our platform,” said AJ Brown, CEO of Apex Service Partners. “Alpine’s support through its industry experience, resources and focus on people supercharged our growth while helping us hire, train and retain exceptional talent. They’ve been a true thought partner for us at each step in our journey and we’re excited to continue to have them by our side as we seek to scale to new heights with the help of continued and new investors alike.”
AJ Brown was part of Alpine’s CEO-in-Residence program, and he previously served as CFO of construction software company Avitru, a former Alpine portfolio company. Apex President Will Matson is an additional example of recruiting through Alpine's talent programs, having been hired through its CEO-in-Training program. Both are excited to continue leading Apex during its next phase of growth.
Evercore Inc. acted as the lead financial advisor along with J.P. Morgan and Cowen for the transaction and Kirkland & Ellis served as legal counsel to Alpine. Morrison Foerster served as debt counsel.
About Apex Service Partners
Apex Service Partners is a residential HVAC, plumbing and electrical services group whose goal is to partner with world-class service providers to build an industry leading national platform. Apex focuses on leveraging the power of people to build a strong network of industry leaders who can share resources, best practices and expertise in order to deliver unparalleled service to customers and opportunities for employees. To learn more about Apex Service Partners, please visit www.apexservicepartners.com.
About Alpine Investors
Alpine Investors is a people-driven private equity firm committed to building enduring companies by working with, learning from, and developing exceptional people. Alpine specializes in investments in the software and services industries. Alpine’s PeopleFirst strategy includes a talent program that allows Alpine to bring leadership to situations where additional or new management is needed post-transaction. Alpine has $16 billion in assets under management as of June 30, 2023, and has three offices in San Francisco, New York, and Salt Lake City.1 For more information, visit www.alpineinvestors.com and https://alpineinvestors.com/terms-conditions/ for full disclaimers including, but not limited to, third-party statements and certifications and Alpine Operations Group.
_____________________________
1 Inclusive of additional commitments to the continuation fund as of October 20, 2023 and fair market value as of June 30, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231025759806/en/
Contact information
Media
Audrey Harris
Head of Marketing
aharris@alpineinvestors.com
Sarah Braunstein
sbraunstein@sloanepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
